Advanced Hemophilia Course on Inhibitors  
October 9-11, 2018  
**Preliminary program**

### Day 1

- **09.30-10.00** Registration
- **10.00-10.30** Welcome and introduction
- **10.30-11.00** Hemophilia management of today and tomorrow with a focus on inhibitor development (JA)
- **11.15-12.00** Laboratory aspects on inhibitor diagnosis and management (KS)
- **12.00-13.00** Lunch
- **13.00-14.00** Immunology (SLD)
- **14.15-15.00** Interactive case discussion (JA)
- **15.00-15.30** Break
- **15.30-16.15** Risk factors for inhibitor formation – *Genetic aspects* (JA)
- **16.15-17.30** Introduction to and preparation of session on evidence-based medicine (EBM)

### Day 2

- **08.30-09.15** Risk factors for inhibitor formation - *Non-genetic aspects* (RL)
- **09.30-10.15** Immune tolerance induction therapy (RL/JA)
- **10.15-10.45** Break
- **10.45-11.15** Inhibitors in non-severe hemophilia (EB)
- **11.30-12.15** Interactive case discussion (RL/JA)
- **12.15-13.00** Lunch
- **13.00-13.45** Conventional and emerging treatment of bleeds and prophylaxis (JA/NGA)
- **14.00-14.45** Surgery in inhibitor patients – management and monitoring (PAH)
- **14.45-15.15** Interactive case discussion – surgery (PAH)
- **15.15-15.45** Break
- **15.45-16.15** Acquired hemophilia (EZ)
- **16.30-17.15** Interactive case discussion – Participants cases (Faculty)
- **19.00-** Dinner

### Day 3

- **08.30-10.00** How to treat failures of ‘conventional ITI’? (RL/JA)
- **10.00-10.30** Break
- **10.30-11.15** Inhibitors in hemophilia B (JA)
- **11.15-12.00** Interactive case discussion – Participants cases (Faculty)
- **12.00-13.00** Lunch
- **13.00-15.00** EBM session including break (Faculty)
- **15.00-15.30** Evaluation and Concluding remarks

### Faculty

- **Prof Jan Austermark, Malmö** (JA)
- **Prof Rolf Ljung, Malmö** (RL)
- **Prof Erik Berntorp, Malmö** (EB)
- **Prof Pål Andre Holme, Oslo** (PAH)
- **Prof Sebastien Lacroix-Desmazes, Paris** (SLD)
- **MD PhD Karin Strandberg, Malmö** (KS)
- **MD PhD Nadine Gretenkort Andersson, Malmö** (NGA)
- **MD PhD Eva Zetterberg, Malmö** (EZ)